Month: March 2024

PharmAla Biotech Signs Sale Agreement with Numinus

Written by Customer Service on March 26, 2024. Posted in Public Companies.

LaNeo Product Data submitted for a Clinical Trial in Canada TORONTO, March 26, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA, OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it had entered into a binding sales agreement with Numinus Wellness Inc. (“Numinus”) (TSX: NUMI, OTCQX: NUMIF) to provide its GMP LaNeo™ MDMA for a prospective clinical trial. “PharmAla wishes Numinus success in their clinical trial application, and looks forward to supporting them in their efforts,” said Nick Kadysh, Founding CEO, PharmAla Biotech. “LaNeo™ is undoubtedly the drug product of choice for MDMA clinical trial practitioners in Canada, and...

Xos, Inc. Accelerates Growth with Strategic Acquisition of ElectraMeccanica

Written by Customer Service on March 26, 2024. Posted in Mergers And Acquisitions.

LOS ANGELES, March 26, 2024 (GLOBE NEWSWIRE) — Xos, Inc. (NASDAQ: XOS), a leading electric truck manufacturer and fleet electrification services provider, today announced that it has closed its acquisition of ElectraMeccanica Vehicles Corp. (NASDAQ: SOLO) (“ElectraMeccanica”), a designer and assembler of electric vehicles. Terms of the acquisition were first announced on January 11, 2024. The all-stock transaction is expected to add approximately $48 million to Xos’ balance sheet and provide growth capital for the company. “The growth capital received in the transaction, combined with our reduction of cash burn, provides an important pathway to profitability as we scale deliveries over the next several quarters,” said Dakota Semler, CEO and Co-Founder of Xos, Inc. “Xos is gross margin positive and has now charted our course to...

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

Written by Customer Service on March 26, 2024. Posted in Earnings Releases And Operating Results.

BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the year ended December 31, 2023 and provides a corporate update. Corporate Highlights from Q4 2023 to DatePresented data at AD/PD 2024 demonstrating mechanism of action of GT-02287, the Company’s lead compound being investigated for the treatment of GBA1 Parkinson’s disease Announced the initiation of the Multiple Ascending Dose (MAD) part of the Phase 1 clinical trial of GT-02287, a novel GCase-targeting small molecule therapy for GBA1 Parkinson’s disease Presented late-breaking data at the WORLDSymposium showing GT-02287 displays neuroprotection...

Yield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for Planting in Canada

Written by Customer Service on March 26, 2024. Posted in Public Companies.

WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today reported that the Plant Biosafety Office (“PBO”) of the Canadian Food Inspection Agency (“CFIA”) recently reviewed information on the Company’s E3902 Camelina sativa (“Camelina”) and determined that E3902 is not a Plant with Novel Trait (PNT) and is not subject to a pre-market notification under Part V of the Seeds Regulations. Yield10’s E3902 Camelina combines genome edits in three proprietary genetic traits, C3008a, C3008b and C3009, that result in an increase in oil production by five percent and produce a lighter seed coat color as compared to the parental Camelina line. E3902 Camelina remains subject to other applicable requirements of the Seeds Act and Regulations...

Surgery Partners, Inc. Announces New Senior Notes Offering

Written by Customer Service on March 26, 2024. Posted in Public Companies.

BRENTWOOD, Tenn., March 26, 2024 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced today that Surgery Center Holdings, Inc., a wholly owned subsidiary of the Company (the “Issuer”), intends to offer, subject to market and other considerations, $600,000,000 aggregate principal amount of senior unsecured notes due 2032 (the “Notes”). The Notes will be guaranteed (the “Guarantees”) on a senior unsecured basis by each domestic wholly-owned subsidiary of the Issuer that guarantees its obligations under its senior secured credit facilities. The terms of the Notes, including interest rate and principal amount, will depend on market conditions at the time of pricing and will be determined by negotiations among Surgery Partners...

Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on March 26, 2024. Posted in Earnings Releases And Operating Results.

U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) — Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023. “Our team’s execution continues to be outstanding, with the filing of our U.S. IND for THB335 ahead of our internal timelines for submission,” said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. “We look forward to the agency’s feedback and the opportunity to initiate clinical studies during the second quarter for this potentially first-in-class oral...

Microchip Technology Expands TrustFLEX Family with CEC1736 Real-time Platform Root of Trust Devices

Written by Customer Service on March 26, 2024. Posted in Public Companies.

TrustFLEX devices along with the Trust Platform Design Suite tool will simplify the enablement of root of trust from concept to production in wide range of applications CHANDLER, Ariz., March 26, 2024 (GLOBE NEWSWIRE) — As technology and cybersecurity standards continue to evolve, Microchip Technology (Nasdaq: MCHP) is helping make embedded security solutions more accessible with its CEC1736 TrustFLEX devices. The CEC1736 Trust Shield family is a microcontroller-based platform root of trust solution enabling cyber resiliency for data centers, telecom, networking, embedded computing and industrial applications. Now, as part of the TrustFLEX platform, the devices are partially configured and provisioned with Microchip-signed Soteria-G3 firmware to reduce the development time needed to integrate platform root of trust. These devices...

Gabelli Global Utility & Income Trust Appoints Nicolas W. Platt to Board of Trustees

Written by Customer Service on March 26, 2024. Posted in Public Companies.

RYE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) — The Board of Trustees of The Gabelli Global Utility & Income Trust (the “Board”) (NYSE American: GLU) (the “Fund”) announced the appointment of Nicolas W. Platt to the Board of the Fund effective February 13, 2024. Mr. Platt is a private investor and is a member of the NYSE American LLC Committee on Securities. In 2018, New Jersey Governor Phil Murphy appointed Mr. Platt to be one of two bipartisan “Czars” to address the State’s property tax crisis. He served as Mayor of the Township of Harding, New Jersey from 2013 to 2016, and currently serves on the Township Committee. From 2009 until 2011, Mr. Platt served as Managing Director of FTI Consulting Inc., an international financial consulting company. Prior to March 2009, he was a senior executive with WPP Group, plc subsidiaries...

GDS Appoints Jamie Khoo As CEO of GDS International

Written by Customer Service on March 26, 2024. Posted in Public Companies.

SHANGHAI, China, March 26, 2024 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS”, “GDSH” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China and South East Asia, today announced the appointment of Ms. Jamie Khoo, currently the Chief Operating Officer (“COO”) of GDS, as the Chief Executive Officer (“CEO”) of DigitalLand Holdings Limited (“GDS International” or “GDSI”), the holding company for GDS’s international data center assets and operations. The appointment is effective at the closing of the Series A capital raise of GDS International which has been announced today. Concurrently, Jamie will step down as the COO of GDS. Her responsibilities as the COO of GDS will be assigned to Mr. Kejing Zhang, SVP, Sales, Ms. Yan Liang, SVP, Operational Excellence,...

GDS Announces Landmark US$587 Million Equity Raise For its International Business

Written by Customer Service on March 26, 2024. Posted in Public Companies.

SHANGHAI, China, March 26, 2024 (GLOBE NEWSWIRE) — GDS Holdings Limited (the “Company” or “GDSH”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China and South East Asia, today announced that GDSH’s wholly-owned subsidiary, DigitalLand Holdings Limited (“GDS International” or “GDSI”), that acts as the holding company for GDSH’s international data center assets and operations, has entered into definitive agreements for certain institutional private equity investors (the “Investors”) to subscribe for US$587 million of Series A convertible preferred shares (the “Series A”) newly issued by GDSI. This transaction is a significant step forward in the Company’s strategy to obtain dedicated financing for the development of its international business on a standalone basis. GDS International...

Month: March 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals